Contineum Therapeutics Inc [CTNM] stock prices are up 29.89% to $5.65 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CTNM shares have gain 51.47% over the last week, with a monthly amount glided 54.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Robert W. Baird started tracking the stock with Outperform rating on October 22, 2024, and set its price target to $32. On April 30, 2024, Stifel initiated with a Buy rating and assigned a price target of $29 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $30 on April 30, 2024. Morgan Stanley initiated its recommendation with a Overweight and recommended $25 as its price target on April 30, 2024.
The stock price of Contineum Therapeutics Inc [CTNM] has been fluctuating between $3.35 and $21.66 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Contineum Therapeutics Inc [NASDAQ: CTNM] shares were valued at $5.65 at the most recent close of the market. An investor can expect a potential return of 183.19% based on the average CTNM price forecast.
Analyzing the CTNM fundamentals
Gross Profit Margin for this corporation currently stands at 0.25% with Operating Profit Margin at -244.11%, Pretax Profit Margin comes in at -205.91%, and Net Profit Margin reading is -205.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.25 and Total Capital is -0.31. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Contineum Therapeutics Inc [NASDAQ:CTNM]’s Current Ratio is 21.47. Further, the Quick Ratio stands at 21.47, while the Cash Ratio is 2.51.
Transactions by insiders
Recent insider trading involved Lorrain Daniel S., Chief Scientific Officer, that happened on Nov 25 ’24 when 1010.0 shares were sold. Chief Scientific Officer, Lorrain Daniel S. completed a deal on Nov 18 ’24 to sell 6190.0 shares. Meanwhile, Officer DANIEL LORRAIN bought 26370.0 shares on Nov 18 ’24.
